Skip to content

A clinical study of multimodal ultrasound to evaluate the effect of neoadjuvant chemotherapy in breast cancer

A clinical study of multimodal ultrasound to evaluate the effect of neoadjuvant chemotherapy in breast cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085035
Enrollment
Unknown
Registered
2024-05-30
Start date
2022-06-08
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Gold Standard:Surgical pathology after the end of neoadjuvant chemotherapy
Index test:Conventional ultrasound imaging, ultrasound elastography, contrast-enhanced ultrasound, breast magnetic resonance, breast CT

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Have an indication for neoadjuvant chemotherapy and receive a standardized chemotherapy regimen 2) At least one target lesion per RECIST criteria 3) Surgery to obtain pathology after completion of neoadjuvant chemotherapy 4) Complete standardized chemotherapy image tracking 5) Understand and willing to sign the informed consent form

Exclusion criteria

Exclusion criteria: 1) Tumor progression, treatment to palliative chemoradiotherapy 2) Clinicopathological data are incomplete 3) Poor imaging quality 4) Psychological, family, social and other factors lead to no informed consent

Design outcomes

Primary

MeasureTime frame
Accuracy;Sensitivity;Specificity;

Countries

China

Contacts

Public ContactXiaoqing Pei

Sun Yat-sen University Cancer Center

peixq@sysucc.org.cn+86 20 8734 3212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026